<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82861">
  <stage>Registered</stage>
  <submitdate>11/06/2008</submitdate>
  <approvaldate>30/10/2008</approvaldate>
  <actrnumber>ACTRN12608000549325</actrnumber>
  <trial_identification>
    <studytitle>The effect of breathing oxygen in patients with asthma.</studytitle>
    <scientifictitle>The effect of high flow oxygen on carbon dioxide levels and ventilation in patients with chronic stable asthma.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>100% oxygen inhaled for 20 minutes through a CPAP mask and tubing. Intervention will be administered to 3 groups of subjects: 1. 18 subjects with Asthma 2. 18 subjects with Chronic Obstructive Pulmonary Disease 3. 18 normal subjects (no respiratory disease)</interventions>
    <comparator>The same treatment (100% oxygen inhaled for 20 minutes through a CPAP mask and tubing) will be given to the 2 control groups: normal subjects and a group of Chronic Obstructive Pulmonary Disease (COPD) subjects</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in PaCO2 measured by a transcutaneous CO2 monitor clipped to the earlobe</outcome>
      <timepoint>After 20 minutes of 100% oxygen inhalation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in ratio of physiological dead space:tidal volume calculated by measuring the mixed exhaled CO2 through a sensor in the mask mouthpiece</outcome>
      <timepoint>After 20 minutes of oxygen inhalation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in minute ventilation (in litres per minute) measured by a flow-meter attached to the mask mouthpiece</outcome>
      <timepoint>After 20 minutes of 100% oxygen inhalation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosis of asthma
2. Forced Expiratory Volume in one second (FEV1) &lt; or = 60% predicted</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Diagnosis of COPD
2. Current or ex cigarette smoking of &gt; 10 pack years
3. Risk factors for hypercapnic respiratory failure (Body Mass Index &gt; 40, severe musculoskeletal weakness, chest wall restriction).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>N/A</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>72</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Kyle Perrin</primarysponsorname>
    <primarysponsoraddress>MRINZ
Level 3
99 The terrace
Wellington</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>Level 3
110 Stanley Street
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>It is well known that high amounts of oxygen can be harmful to patients with emphysema when they come to the emergency department. There is also a small amount of research to suggest that it could be harmful to patients with severe asthma as well, although they are routinely given high flow oxygen. The main purpose of this study is to see if giving 100% oxygen to asthmatics causes a rise in harmful carbon dioxide, and if so, what is the mechanism?</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health 
1 - 3 The Terrace 
PO Box 5013 
Wellington</ethicaddress>
      <ethicapprovaldate>20/05/2008</ethicapprovaldate>
      <hrec>CEN/08/04/013</hrec>
      <ethicsubmitdate>19/03/2008</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kyle Perrin</name>
      <address>MRINZ
Level 3
99 The terrace
Wellington</address>
      <phone>+64 4 4729120</phone>
      <fax />
      <email>kyle.perrin@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kyle Perrin</name>
      <address>MRINZ
Level 3
99 The terrace
Wellington</address>
      <phone>+64 4 4729120</phone>
      <fax />
      <email>kyle.perrin@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kyle Perrin</name>
      <address>MRINZ
Level 3
99 The terrace
Wellington</address>
      <phone>+64 4 4729120</phone>
      <fax />
      <email>kyle.perrin@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>